Liver Diseases  >>  dusigitumab (MEDI-573)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dusigitumab (MEDI-573) / AstraZeneca
NCT01498952: MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Completed
1b/2
6
US
MEDI-573 (1 of 3 doses), Sorafenib
MedImmune LLC
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
04/13
04/13

Download Options